3,4-二氢-1-(羟基甲基)-2(1h)-异喹啉羧酸 1,1-二甲基乙酯 | 954239-58-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 中文名称: 3,4-二氢-1-(羟基甲基)-2(1h)-异喹啉羧酸 1,1-二甲基乙酯
• 中文别名: 1-羟甲基-3,4-二氢-1H-异喹啉-2-羧酸叔丁酯；3,4-二氢-1-(羟基甲基)-2(1h)-异喹啉羧酸1,1-二甲基乙酯
• 英文名称: tert-Butyl 1-(hydroxymethyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate
• 英文别名: tert-butyl 1-(hydroxymethyl)-3,4-dihydro-1H-isoquinoline-2-carboxylate
• CAS: 954239-58-8
• 化学式: C₁₅H₂₁NO₃
• 分子量: 263.337
• InChiKey: PNLHOCUNLNUFIH-UHFFFAOYSA-N

物化性质

• 沸点：
  392.9±35.0 °C(Predicted)
• 密度：
  1.129±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P264,P280,P302+P352,P337+P313,P305+P351+P338,P362+P364,P332+P313
• 危险性描述：
  H315,H319

反应信息

• 作为反应物：
  描述：

  3,4-二氢-1-(羟基甲基)-2(1h)-异喹啉羧酸 1,1-二甲基乙酯 在 戴斯-马丁氧化剂 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 48.0h， 生成 tert-butyl 1-formyl-3,4-dihydro-1H-isoquinoline-2-carboxylate
  参考文献：
  名称：

  Discovery of Tetrahydroisoquinoline-Based CXCR4 Antagonists

  摘要：

  A de novo hit-to-lead effort involving the redesign of benzimidazole-containing antagonists of the CXCR4 receptor resulted in the discovery of a novel series of 1,2,3,4-tetrahydroisoquinoline (TIQ) analogues. In general, this series of compounds show good potencies (3-650 nM) in assays involving CXCR4 function, including both inhibition of attachment of X4 HIV-1(IIIB) virus in MAGI-CCR5/CXCR4 cells and inhibition of calcium release in Chem-1 cells. Series profiling permitted the identification of TIQ(R)-stereoisomer 15 as a potent and selective CXCR4 antagonist lead candidate with a promising in vitro profile. The drug-like properties of 15 were determined in ADME in vitro studies, revealing low metabolic liability potential. Further in vivo evaluations included pharmacokinetic experiments in rats and mice, where 15 was shown to have oral bioavailability (F = 63%) and resulted in the mobilization of white blood cells (WBCs) in a dose-dependent manner.

  DOI：

  10.1021/ml400183q
• 作为产物：
  描述：

  2-N-Boc-1,2,3,4-四氢异喹啉-1-羧酸 在 dimethyl sulfide borane 作用下， 以 四氢呋喃 为溶剂， 反应 25.0h， 生成 3,4-二氢-1-(羟基甲基)-2(1h)-异喹啉羧酸 1,1-二甲基乙酯
  参考文献：
  名称：

  Discovery of Tetrahydroisoquinoline-Based CXCR4 Antagonists

  摘要：

  A de novo hit-to-lead effort involving the redesign of benzimidazole-containing antagonists of the CXCR4 receptor resulted in the discovery of a novel series of 1,2,3,4-tetrahydroisoquinoline (TIQ) analogues. In general, this series of compounds show good potencies (3-650 nM) in assays involving CXCR4 function, including both inhibition of attachment of X4 HIV-1(IIIB) virus in MAGI-CCR5/CXCR4 cells and inhibition of calcium release in Chem-1 cells. Series profiling permitted the identification of TIQ(R)-stereoisomer 15 as a potent and selective CXCR4 antagonist lead candidate with a promising in vitro profile. The drug-like properties of 15 were determined in ADME in vitro studies, revealing low metabolic liability potential. Further in vivo evaluations included pharmacokinetic experiments in rats and mice, where 15 was shown to have oral bioavailability (F = 63%) and resulted in the mobilization of white blood cells (WBCs) in a dose-dependent manner.

  DOI：

  10.1021/ml400183q

文献信息

• Dpp-IV Inhibitors
  申请人：Edwards Paul John

  公开号：US20080176838A1

  公开（公告）日：2008-07-24

  The invention relates to compounds of formula (I) wherein R 1-9 , Z, n, X, A, and R b have the meaning as cited in the description and the claims. Said compounds are useful as DPP-IV inhibitors. The invention also relates to the preparation of such compounds as well as the production and use thereof as medicament for the treatment of type 2 diabetes mellitus, obesity and lipid disorders.

  该发明涉及式(I)的化合物，其中R1-9、Z、n、X、A和Rb的含义如描述和权利要求中所述。所述化合物可用作DPP-IV抑制剂。该发明还涉及制备这种化合物以及将其作为药物用于治疗2型糖尿病、肥胖和脂质紊乱的生产和使用。
• [EN] HISTONE DEMETHYLASE INHIBITORS<br/>[FR] INHIBITEURS DE L'HISTONE DÉMÉTHYLASE
  申请人：QUANTICEL PHARMACEUTICALS INC

  公开号：WO2015200709A1

  公开（公告）日：2015-12-30

  The present disclosure relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyridine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.

  本公开涉及治疗癌症和肿瘤疾病的组合物和方法。本文提供了替代吡啶衍生物化合物和包含该化合物的制药组合物。该化合物和组合物对于抑制组蛋白去甲基化酶具有用途。此外，该化合物和组合物对于治疗癌症，例如前列腺癌、乳腺癌、膀胱癌、肺癌和/或黑色素瘤等具有用途。
• HISTONE DEMETHYLASE INHIBITORS
  申请人：CELGENE QUANTICEL RESEARCH, INC.

  公开号：US20160332970A1

  公开（公告）日：2016-11-17

  The present disclosure relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyridine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.

  本公开涉及治疗癌症和肿瘤性疾病的组合物和方法。本文提供了取代吡啶衍生物化合物和包含该化合物的制药组合物。该化合物和组合物对于抑制组蛋白去甲基化酶具有用处。此外，该化合物和组合物对于治疗癌症，如前列腺癌、乳腺癌、膀胱癌、肺癌和/或黑色素瘤等具有用处。
• Soluble guanylate cyclase activators
  申请人：Brenneman Jehrod Burnett

  公开号：US08569339B2

  公开（公告）日：2013-10-29

  The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, A and B are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

  本发明涉及公式（I）的化合物及其药学上可接受的盐，其中R1，R2，R3，R4，R5，R6，A和B的定义如本文所述。本发明还涉及包含这些化合物的药物组合物，使用这些化合物治疗各种疾病和障碍的方法，制备这些化合物的过程以及在这些过程中有用的中间体。
• SOLUBLE GUANYLATE CYCLASE ACTIVATORS
  申请人：Brenneman Jehrod Burnett

  公开号：US20130065918A1

  公开（公告）日：2013-03-14

  The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , A and B are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

  本发明涉及式(I)的化合物及其药学上可接受的盐，其中R1，R2，R3，R4，R5，R6，A和B的定义如本文所述。本发明还涉及包含这些化合物的制药组合物，使用这些化合物治疗各种疾病和障碍的方法，制备这些化合物的过程以及这些过程中有用的中间体。